Viatris (NASDAQ: VTRS) makes both generic and branded drugs and its stock looks like a potential steal of a deal at the moment. It trades at less than 6 times its earnings, and it pays a dividend that today yields just over 5%.

But when a stock is so heavily discounted, there's usually more to the story. That could be why, at the start of 2023, investors have been dumping -- not buying -- shares of Viatris. The stock price is down 15.2% thus far in 2023 (the S&P 500 is up 2.9% by comparison).

Here's a look at what's wrong with this beleaguered stock and whether its dividend is safe.

Continue reading

Source Fool.com